Wall Street analysts predict that Kezar Life Sciences Inc (NASDAQ:KZR) will report earnings per share (EPS) of ($0.55) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Kezar Life Sciences’ earnings. The highest EPS estimate is ($0.45) and the lowest is ($0.63). The company is expected to announce its next quarterly earnings results on Thursday, February 14th.
On average, analysts expect that Kezar Life Sciences will report full-year earnings of ($2.64) per share for the current financial year, with EPS estimates ranging from ($3.11) to ($2.10). For the next financial year, analysts forecast that the business will post earnings of ($2.38) per share, with EPS estimates ranging from ($2.84) to ($2.14). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that follow Kezar Life Sciences.
Kezar Life Sciences (NASDAQ:KZR) last announced its quarterly earnings data on Thursday, November 8th. The company reported ($0.30) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.18.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC lifted its stake in shares of Kezar Life Sciences by 68.4% in the 3rd quarter. FMR LLC now owns 2,530,381 shares of the company’s stock worth $54,175,000 after purchasing an additional 1,027,805 shares during the period. Cowen Inc. bought a new position in shares of Kezar Life Sciences in the 2nd quarter worth approximately $18,207,000. Frazier Management LLC bought a new position in shares of Kezar Life Sciences in the 2nd quarter worth approximately $4,325,000. BlackRock Inc. lifted its stake in shares of Kezar Life Sciences by 2,314.5% in the 3rd quarter. BlackRock Inc. now owns 241,446 shares of the company’s stock worth $5,169,000 after purchasing an additional 231,446 shares during the period. Finally, Acuta Capital Partners LLC bought a new position in shares of Kezar Life Sciences in the 2nd quarter worth approximately $1,730,000. Institutional investors and hedge funds own 42.19% of the company’s stock.
KZR traded up $0.58 during midday trading on Friday, hitting $24.58. 29,200 shares of the company traded hands, compared to its average volume of 59,646. Kezar Life Sciences has a 52 week low of $14.77 and a 52 week high of $26.86.
About Kezar Life Sciences
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Featured Story: Hedge Funds – Risk or Reward?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.